Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background: Previous findings on using Glucagon-like peptide-1 receptor agonist (GLP1-RA) as an antidepressant were conflicting, lacking large-scale studies. We used population-based data to investigate depression and anxiety risk in diabetic patients receiving the medication. Methods: From claims records of the National Health Insurance Research Database (NHIRD) of Taiwan, we identified cohorts of 10,690 GLP1-RA users and 42,766 propensity score-matched patients without GLP1-RA use from patients with diabetes mellitus (DM) diagnosed in 2011–2017, matched by age, gender, index year, occupation, urbanization, comorbidities, and medications. Incidence, hazard ratios (HR) and 95% confidence interval (CI) of depression and/or anxiety were estimated by the end of 2017. Results: The overall combined incidence of anxiety and/or depression was lower in GLP1-RA users than in non-users (6.80 versus 9.36 per 1,000 person-years), with an adjusted HR adjusted hazard ratio (aHR) of 0.8 (95% CI: 0.67–0.95) after controlling for covariates. The absolute incidence reduction was greater in anxiety (2.13 per 1,000 person-years) than in depression (0.41 per 1,000 person-years). The treatment effectiveness was significant for women. Patients taking GLP1-RA for longer than 180 days had the incidence of anxiety reduced to 2.93 per 1,000 person-years, with an aHR of 0.41 (95%CI: 0.27–0.61), compared to non-users. Dulaglutide could significantly decrease risks of both anxiety and depression. Conclusion: Patients with DM receiving GLP1-RA therapy have a greater reduction of the risk of anxiety than that of depression. Our findings strengthen previous research that advocated possible anti-depressant or anxiolytic effects of GLP1-RA and may lead to improved treatment adherence among patients with DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 1×
“Diabetes mellitus (DM) is a group of endocrinological and metabolic disorders affecting approximately 422 million patients worldwide (Saeedi et al., 2019).”
BackgroundThe Prevalence of Comorbid Depression in Adults With Diabetes
Anderson, R. J., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1069 · Cited by 3,926 · cited 2×
“Considerable evidence has also associated DM with increased risk of incident or recurrent depression (Gavard et al., 1993; Lustman et al., 2000; Anderson et al., 2001; Snoek et al., 2015; Chima et al., 2017; Khaledi et al., 2019).”
BackgroundMultimorbidity and depression: A systematic review and meta-analysis
Read, J. R., Sharpe, L., Modini, M., & Dear, B. F. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.009 · Cited by 869
Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond
Michopoulos, V., Powers, A., Gillespie, C. F., Ressler, K. J., & Jovanovic, T. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.146 · Cited by 786
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Major Depression and Activation of The Inflammatory Response System
Maes, M. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_2 · Cited by 617 · cited 1×
“…are characterized by increased circulating inflammatory cytokines, including interleukin (IL)-1, IL-6, tumor necrosis factor (TNF), their soluble receptors, and acute phase reactants such as C-reactive protein (CRP) (Maes et al., 1992; Maes, 1999; Sluzewska, 1999; Michopoulos et al., 2017).”
BackgroundHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 1×
“On the other hand, GLP-1 RA crossed the BBB successfully (Hunter and Hölscher, 2012; Athauda and Foltynie, 2016).”
BackgroundConstructs of depression and distress in diabetes: time for an appraisal
Snoek, F. J., Bremmer, M. A., & Hermanns, N. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00135-7 · Cited by 449
Leach, L. S., Christensen, H., Mackinnon, A. J., Windsor, T. D., & Butterworth, P. (2008) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-008-0388-z · Cited by 413
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383 · cited 1×
“On the other hand, GLP-1 RA crossed the BBB successfully (Hunter and Hölscher, 2012; Athauda and Foltynie, 2016).”
Background
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Catalani, V., Martinotti, G., Sensi, S. L., & Schifano, F. (2023) · Brain Sciences · doi:10.3390/brainsci13111503 · Cited by 104
Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B., Kushner, R. F., McGowan, B., Overvad, M., & Fink-Jensen, A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.4346 · Cited by 96
Cooper, D. H., Ramachandra, R., Ceban, F., Di Vincenzo, J. D., Rhee, T. G., Mansur, R. B., Teopiz, K. M., Gill, H., Ho, R., Cao, B., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.041 · Cited by 79
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
“GLP-1 RAs not only ameliorate insulin resistance and microvascular injury [84], which are significant determinants of depression in T2DM, but also enhance dopamine metabolism and stimulate growth factor signaling pathways, suggesting potential neuro-protective functions [85,86].”
Tang, H., Lu, Y., Donahoo, W. T., Shao, H., Shi, L., Fonseca, V. A., Guo, Y., Bian, J., & Guo, J. (2024) · Annals of Internal Medicine · doi:10.7326/m24-0329 · Cited by 40
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“This suggests an interaction between GLP-1R, the central and peripheral nervous systems, and estrogen in anorexigenic actions [343].”
Li, S., Sabbah, S. G., Kwan, A. T. H., & McIntyre, R. S. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.08.002 · Cited by 19
Metadata
- Authors
- Tsai, W.-H., Sung, F.-C., Chiu, L.-T., Shih, Y.-H., Tsai, M.-C., & Wu, S.-I.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-02-23
- Volume
- 13
- Pages
- 765446-765446
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W4213337343
- Cited by
- 44
- References
- 29
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.